Journal article icon

Journal article

OvAd1, a novel, potent, and selective chimeric oncolytic virus developed for ovarian cancer by 3D-directed evolution

Abstract:

Effective therapeutics for ovarian cancer continue to be urgently needed, particularly for chemotherapy-resistant cases. Here we present both a 3D-Matrigel culture-based expansion of our directed evolution method for generation of oncolytic virotherapies and two promising ovarian-cancer targeted oncolytic viruses, OvAd1 and OvAd2. OvAd1 was developed using Matrigel cell cultures, whereas OvAd2 was developed in parallel using traditional monolayer tissue culture methods. Both viruses are poten...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.omto.2016.12.001

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
Bayer Healthcare A.G. More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Molecular Therapy - Oncolytics Journal website
Volume:
4
Pages:
55-66
Publication date:
2017-03-17
Acceptance date:
2016-12-01
DOI:
ISSN:
2372-7705
Source identifiers:
688871
Language:
English
Keywords:
Pubs id:
pubs:688871
UUID:
uuid:7a50d6d9-bf16-4265-b050-ac7b754ac539
Local pid:
pubs:688871
Deposit date:
2017-07-25

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP